Johnson & Johnson (NYSE:JNJ) Stock Position Increased by Selway Asset Management

Selway Asset Management increased its stake in Johnson & Johnson (NYSE:JNJGet Rating) by 1.9% during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 12,810 shares of the company’s stock after acquiring an additional 240 shares during the quarter. Selway Asset Management’s holdings in Johnson & Johnson were worth $2,270,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently modified their holdings of JNJ. EagleClaw Capital Managment LLC grew its holdings in shares of Johnson & Johnson by 2.0% in the 3rd quarter. EagleClaw Capital Managment LLC now owns 17,516 shares of the company’s stock worth $2,824,000 after acquiring an additional 337 shares during the last quarter. Dark Forest Capital Management LP acquired a new position in shares of Johnson & Johnson in the 3rd quarter worth $102,000. Balyasny Asset Management LLC grew its holdings in shares of Johnson & Johnson by 70.4% in the 3rd quarter. Balyasny Asset Management LLC now owns 586,748 shares of the company’s stock worth $94,760,000 after acquiring an additional 242,366 shares during the last quarter. Migdal Insurance & Financial Holdings Ltd. grew its holdings in shares of Johnson & Johnson by 290.7% in the 3rd quarter. Migdal Insurance & Financial Holdings Ltd. now owns 293 shares of the company’s stock worth $47,000 after acquiring an additional 218 shares during the last quarter. Finally, Psagot Value Holdings Ltd. grew its holdings in shares of Johnson & Johnson by 51.4% in the 3rd quarter. Psagot Value Holdings Ltd. now owns 530 shares of the company’s stock worth $86,000 after acquiring an additional 180 shares during the last quarter. Institutional investors and hedge funds own 68.78% of the company’s stock.

In other news, insider William Hait sold 29,699 shares of Johnson & Johnson stock in a transaction that occurred on Thursday, April 21st. The shares were sold at an average price of $183.58, for a total value of $5,452,142.42. Following the transaction, the insider now owns 80,236 shares of the company’s stock, valued at $14,729,724.88. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, EVP Kathryn E. Wengel sold 40,000 shares of Johnson & Johnson stock in a transaction that occurred on Friday, June 10th. The shares were sold at an average price of $173.00, for a total transaction of $6,920,000.00. Following the completion of the transaction, the executive vice president now directly owns 71,311 shares in the company, valued at approximately $12,336,803. The disclosure for this sale can be found here. Insiders have sold 78,161 shares of company stock valued at $13,895,302 in the last ninety days. Company insiders own 0.35% of the company’s stock.

A number of research analysts have recently weighed in on the company. Credit Suisse Group lifted their price target on Johnson & Johnson from $200.00 to $205.00 and gave the company an “outperform” rating in a report on Wednesday, April 20th. The Goldman Sachs Group lifted their price target on Johnson & Johnson from $163.00 to $181.00 and gave the company a “neutral” rating in a report on Tuesday, April 12th. StockNews.com upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Tuesday, May 17th. Daiwa Capital Markets assumed coverage on Johnson & Johnson in a report on Wednesday. They set an “outperform” rating on the stock. Finally, Bank of America assumed coverage on Johnson & Johnson in a report on Wednesday, March 2nd. They set a “neutral” rating on the stock. Four investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $190.50.

JNJ opened at $175.74 on Thursday. The stock has a market cap of $462.44 billion, a price-to-earnings ratio of 23.68, a PEG ratio of 3.35 and a beta of 0.66. Johnson & Johnson has a 1 year low of $155.72 and a 1 year high of $186.69. The company has a current ratio of 1.39, a quick ratio of 1.14 and a debt-to-equity ratio of 0.39. The stock has a fifty day moving average price of $177.66 and a 200 day moving average price of $173.09.

Johnson & Johnson (NYSE:JNJGet Rating) last released its quarterly earnings data on Tuesday, April 19th. The company reported $2.67 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.60 by $0.07. The firm had revenue of $23.43 billion during the quarter, compared to analysts’ expectations of $23.62 billion. Johnson & Johnson had a return on equity of 36.59% and a net margin of 20.90%. The business’s revenue for the quarter was up 5.0% on a year-over-year basis. During the same quarter last year, the firm earned $2.59 earnings per share. As a group, sell-side analysts forecast that Johnson & Johnson will post 10.23 earnings per share for the current fiscal year.

The business also recently announced a quarterly dividend, which was paid on Tuesday, June 7th. Investors of record on Tuesday, May 24th were issued a $1.13 dividend. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.06. This represents a $4.52 annualized dividend and a yield of 2.57%. The ex-dividend date was Monday, May 23rd. Johnson & Johnson’s payout ratio is 60.92%.

About Johnson & Johnson (Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Read More

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.